Seroprevalence of SARS-CoV-2–Specific Antibodies among Quarantined Close Contacts of COVID-19 Patients, Faroe Islands, 2020
Maria Skaalum Petersen
, Marnar Fríðheim Kristiansen, Halla Weihe Reinert, Jógvan Páll Fjallsbak, Debes Hammershaimb Christiansen, Shahin Gaini, Bjarni á Steig, Lars Fodgaard Møller, Marin Strøm, and Pál Weihe
Author affiliations: University of the Faroe Islands, Tórshavn, Faroe Islands (M.S. Petersen, M.F. Kristiansen, S. Gaini, M. Strøm, P. Weihe); The Faroese Hospital System, Tórshavn (M.S. Petersen, H.W. Reinert, P. Weihe); National Hospital of the Faroe Islands, Tórshavn (M.F. Kristiansen, S. Gaini, B. á Steig); COVID-19 Task Force, Ministry of Health, Tórshavn (M.F. Kristiansen, B. á Steig); Faroese Food and Veterinary Authority, Tórshavn (J.P. Fjallsbak, D.H. Christiansen); Odense University Hospital, Odense, Denmark (S. Gaini); University of Southern Denmark, Odense (S. Gaini); Chief Medical Officer Office, Tórshavn (L.F. Møller); Statens Serum Institut, Copenhagen, Denmark (M. Strøm)
Main Article
Figure
Figure. Recruitment of quarantined close contacts of coronavirus disease patients for study of seroprevalence of severe acute respiratory syndrome coronavirus 2–specific antibodies, Faroe Islands, 2020.
Main Article
Page created: August 06, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.